Kornimate/medical-research-clean huggingface dataset:
study of glutamine as prophylaxis for irinotecan induced diarrhea

Conditions: Metastatic Colorectal Cancer

Summary: irinotecan (7-ethyl-10- {4(-1-piperidino)-1-piperidino} carbonyloxy camptothecin) is a semisynthetic camptothecin derivative introduced in the 1980's. irinotecan is a prodrug metabolized by carboxylesterases to an active metabolite 7-ethyl-10-hydroxy-camptothecin (sn38). sn38 exerts its cytotoxic effect by forming stable complexes with topoisomerase i and dna. these complexes collide with replication forks and cause breaks in dna. studies substantiated irinotecan's activity in 5fu resistant colorectal cancer and led to its approval for treatment of 5fu resistant colorectal cancer in the united states, canada and europe.colorectal cancer studies demonstrated that single agent irinotecan's dose limiting toxicity was diarrhea occurring 5 to 6 days after its administration. high dose loperamide at first occurrence of diarrhea has decreased the incidence of diarrhea but the incidence of grade 3/4 diarrhea remains high at 28 to 40%.


Eligibility criteria:
inclusion criteria: * metastatic colorectal cancer to be treated with folfiat chemo exclusion criteria: * severely abnormal liver and kidney function

Keywords: irinotecan 5fu amino acids heat shock protein
combination of dental bleaching techniques, randomized clinical trial

Conditions: Tooth Stain

Summary: to determine the effectiveness of combining different concentrations of hydrogen peroxide and carbamide used during tooth bleaching.

120 patiens over 18 years old. design: hydrogen peroxide (hp) carbamide peroxide (cp) group 1: cp 10% + hp 40% group 2: cp 15% + hp 40% group 3: cp 20% + hp 40% group 4: hp 10% + hp 40%

Eligibility criteria:
inclusion criteria: * 18 - 45 years old * student, teacher or administrative personnel at unibe. exclusion criteria: * dental hypersensitivity * periodontal disease * active caries lesions * allergy to latex * orthodontic treatment

Keywords: peroxide
in vivo corneal confocal microscopy for non-invasive assessment of diabetic peripheral neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: clinical in vivo confocal microscopy (ivcm) is a relatively new technique of corneal evaluation that permits non-invasive imaging of corneal structures on the cellular level. precise anatomic characterization of corneal structures, including corneal nerves, can be rapidly performed with high resolution.

evaluation of the corneal nerve layer with ivcm provides a method of direct visualization of peripheral small fiber nerves and a quantifiable assessment of nerve abnormalities in a low risk, non-invasive manner. therefore, our goal is to develop a non-invasive diagnostic protocol as a quantitative tool for the evaluation of dpn. the protocol and the tool we seek to develop could ultimately be used in large-scale clinical trials and in clinical practice to assess dpn severity and progression. we hypothesize that in vivo confocal imaging of the corneal nerve layer is a clinically viable method to assess and quantify systemic peripheral nerve health. we emphasize that this imaging method can be used in both humans and animal models to provide quantifiable, longitudinal data on the same live individual to advance our understanding of the development and progression of dpn, and to evaluate treatment effectiveness.

Eligibility criteria:
inclusion criteria: * diabetes exclusion criteria: * history of laser eye surgery, corneal disease, multiple sclerosis, parkinson's disease, or any known systemic neuropathy.
adme study of [14^c]-ibrexafungerp in healthy male subjects

Conditions: Fungal Disease

Summary: this is a phase 1, open-label, single center, non-randomized study to evaluate the absorption, distribution, metabolism and excretion (adme) of an oral solution of radiolabeled ibrexafungerp following repeat administration in healthy male subjects. all subjects will undergo preliminary screening procedures, will remain the clinical unit for approximately 26 days and will receive radiolabeled ibrexafungerp, orally for 3 days.


Eligibility criteria:
inclusion criteria: * healthy males aged 30 to 65 years willing and able to sign and informed consent. exclusion criteria: * clinically significant medical history or concurrent medical conditions included but not limited to infections, liver or kidney disease * use of certain concomitant medications * history of smoking or alcohol abuse
study of the therapeutic effects of naohuan dan and idebenone in treating mild cognitive impairment with kidney deficiency and phlegm stasis

Conditions: Mild Cognitive Impairment

Summary: this study conducted a retrospective analysis of 64 patients with mild cognitive impairment of the kidney deficiency phlegm and stasis type who underwent treatment with naohuan dan combined with idebenone. the patients' cognitive function was evaluated using the mini-mental state examination (mmse) and the montreal cognitive assessment (moca) before and after treatment. daily living abilities were assessed using the activities of daily living (adl) scale, depression status was evaluated using the geriatric depression scale (gds), and the severity of traditional chinese medicine (tcm) syndrome was assessed using the tcm diagnostic scale. peripheral blood from the patients was also collected for analysis of neuron-specific enolase (nse) and inflammatory factors. the aim was to evaluate the safety and feasibility of using naohuan dan combined with idebenone for the treatment of mild cognitive impairment of the kidney deficiency phlegm and stasis type.


Eligibility criteria:
inclusion criteria: * diagnosis in accordance with both chinese medicine and western medicine. * age between 55 and 85 years, with no gender restrictions. * a score between 21 and 26 on the mini-mental state examination (mmse), with 1 point for primary school education. * willingness to participate in the study and signing of the informed consent form. exclusion criteria: * patients with severely impaired heart, liver, kidney, or other organs functions. * patients with neurological diseases that affect brain function and cognitive impairment. * patients with severe depression or other mental illnesses. * patients with poor compliance or cooperation who were unable to complete the study according to the protocol.
minimally invasive benign hysterectomy

Conditions: Menorrhagia; Metrorrhagia; Uterine Fibroids; Cervical Dysplasia

Summary: a randomised controlled trial comparing hysterectomy by minimally invasive surgical methods; robotic hysterectomy versus vaginal hysterectomy or traditional laparoscopic hysterectomy; outcome and cost analyses.

laparoscopic surgery is advantageous compared to open surgery in terms of patient morbidity, shorter hospitalization and a more rapid return to daily activities. robot-assisted laparoscopic surgery have facilitated a higher proportion of minimally invasive surgery first and foremost within gynecologic oncology.it is not clear whether or not this is true for less advanced surgery where a vaginal approach or a traditional laparoscopic approach is possible. robot-assisted surgery is associated with additional cost due to investment and more expensive surgical equipment. the study is performed to investigate whether or not performing hysterectomy for benign conditions with robotic surgery will be advantageous in terms of shorter operating time, less complications, less conversions to open surgery, and shorter hospital stay in comparison to other minimally invasive procedures such as vaginal hysterectomy and traditional laparoscopic hysterectomy.

Eligibility criteria:
inclusion criteria: * indication for hysterectomy for benign disease or prophylactic surgery due to hereditary cancer * size of uterus and vagina allows for retrieval by the vaginal route * maximum uterine size equivalent to 16 weeks of pregnancy * informed consent exclusion criteria: * malignant disease * known extensive intra-abdominal adhesions * anaesthesiological contraindications to laparoscopic surgery * women with pacemaker or other implants where electrosurgery is to be avoided * immunoincompetent women * simultaneous need for prolapse surgery * women with known defects of the hemostasis * allergies towards metronidazole and doxycycline * inability to understand patient information
frailty trajectories and their association with health outcomes

Conditions: Frailty Syndrome

Summary: frailty is common in gastric cancer survivors and seriously affects their prognosis. multiple longitudinal follow-up assessment of frailty could provide a better understanding of the frailty change of individuals. our aims were to identify the longitudinal trajectories of frailty and estimate their association with health outcomes in elderly gastric cancer survivors.

our study suggested the significant heterogeneity in frailty trajectories among elderly gastric cancer survivors, and that different trajectories had different effects on health outcomes. our results infer the necessity for prevention strategies in elderly gastric cancer survivors to manage heterogeneous frailty trajectories.

Eligibility criteria:
inclusion criteria: * diagnosed with gastric cancer by endoscopy or pathology; * received radical gastrectomy the first time; * aged ≥60 years; * been able to communicate simply in writing and verbal; * completed the data collection of all follow-up points. exclusion criteria: * received radiotherapy or chemotherapy before surgery; * had other sites of malignant tumors; * complicated with severe heart, liver, lung and renal insufficiency; * had physical disability.
improving pain management in patients with nonhematologic cancer

Conditions: Pain; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: a pain assessment and management system for people with cancer may help doctors accurately assess and plan more effective pain treatment for patients who have cancer. purpose: clinical trial to determine the effectiveness of a pain assessment and management system in improving pain management in patients who have nonhematologic cancer.

objectives: * develop and test a pain assessment and management system for people with cancer (pams-pc). * obtain feedback from patients with non-hematologic malignancies on the proposed features of the system and its usability and effectiveness. outline: this is a multicenter study. the study contains 3 parts. patients in part ii are assigned to 1 of 2 assessment groups. * part i: patients participate in a focus interview by telephone over approximately 45 minutes. the interview includes discussion of beliefs and concerns regarding pain and its management, strategies used by the patient for managing pain, the features of the proposed pain assessment and management system for people with cancer (pams-pc), and reactions of the patients to each proposed component of the system. * part ii: * group a: patients participate in an assessment session over approximately 90 minutes, comprising completion of a questionnaire followed by use of a test version of the pams-pc. * group b: patients use the pams-pc first followed by completion of the questionnaire. thirty patients are then randomly selected from the 2 groups to repeat use of the pams-pc 3 hours after the initial assessment. * part iii: patients participate in a patient acceptance test over 30-60 minutes, in which patients test the demo version of the system, complete an evaluation questionnaire, and provide feedback by telephone. projected accrual: a total of 180 patients (10 for part i, 150 (75 per group) for part ii, and 20 for part iii) will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of non-hematologic cancer patient characteristics: age: * 18 and over performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified

Keywords: unspecified adult solid tumor, protocol specific pain
a study of mabthera (rituximab) plus chlorambucil in participants with chronic lymphocytic leukemia.

Conditions: Lymphocytic Leukemia, Chronic

Summary: this single arm study will assess the safety and effect on response rate of a combination of rituximab and chlorambucil in previously untreated participants with b-cell chronic lymphocytic leukemia. participants will receive 6 monthly cycles of combination treatment, followed by up to 6 cycles of chlorambucil alone. rituximab will be administered on day 1 of each cycle, at a dose of 375 milligrams per square meter (mg/m\^2) intravenously (iv) in cycle 1, and 500 mg/m\^2 in subsequent cycles, and chlorambucil will be administered on days 1-7 of each cycle at a dose of 10 mg/m\^2/day per oral (po).


Eligibility criteria:
inclusion criteria: * previously untreated participants with cluster of differentiation 20 (cd20) positive b-cell chronic lymphocytic leukemia; * participants with progressive binet stage b, or c requiring therapy according to national cancer institute (nci) criteria; * eastern cooperative oncology group (ecog) performance status \<=2. exclusion criteria: * previous treatment for chronic lymphocytic leukaemia (cll); * known concomitant hematological malignancy; * transformation to aggressive b-cell malignancy; * history of severe cardiac disease; * known hypersensitivity or anaphylactic reactions to murine antibodies.
urological complications and management after gynecological operations

Conditions: Urological Injury; Gynecologic Disease

Summary: objective: in the study, investigators aimed to evaluate the urological complications of gynecologic operations in a tertiary academic center and to evaluate the treatment methods of these complications. methods: the files of all patients who underwent gynecological surgery between january 2016 and january 2019 were retrospectively reviewed. the age of patients with urological complications, american anesthesia society score, menopausal status, body mass index (bmi), preoperative hemoglobin level, postoperative hemoglobin level and hospitalization duration and number of previous surgeries were recorded. in addition, the patients with urological complications were evaluated in terms of the indications for surgery, type of surgery, type of urological complication and the way of treatment of the complication.

in women, the anatomical localization of urinary and genital tracts is very close to each other. this proximity can lead to injuries during pelvic operations. advances in gynecologic operation techniques and the growing experience of gynecologists may suggest a decrease in urological injuries. however, according to the literature, gynecologists face approximately 0.2% to 1% urinary tract injuries during pelvic surgeries. the increase in the number of recurrent surgeries and adverse situations encountered during the operations such as adhesions and anatomical variations factor into the persistence of urologic complications. investigators aimed to evaluate the urological complications of gynecologic operations in a tertiary academic center and to evaluate the treatment methods of these complications. the files of all patients who underwent gynecological surgery between january 2016 and january 2019 were retrospectively reviewed. the age of patients with urological complications, american anesthesia society score, menopausal status, body mass index (bmi), preoperative hemoglobin level, postoperative hemoglobin level and hospitalization duration and number of previous surgeries were recorded. in addition, the patients with urological complications were evaluated in terms of the indications for surgery, type of surgery, type of urological complication and the way of treatment of the complication.

Eligibility criteria:
inclusion criteria: -gynecologic operations with urologic complications exclusion criteria: * patients with incomplete data and patients who underwent obstetric operations * patients aged under 18 * patients who were operated under emergency conditions
a study for pre-diabetic patients with cholesterol lowering drugs

Conditions: Pre-diabetes

Summary: the purpose of this research study is to examine if a combination of a cholesterol lowering-drug, simvastatin, with a sugar-lowering drug called rosiglitazone is more effective in improving vascular inflammation (irritation of the vessels that transport your blood) and other cardiovascular risk factors than the taking of simvastatin alone.

age 21-75 years metabolic syndrome (must have 3 of the 5 components) elevated waist circumference \>40inches in men, \>35 inches in women elevated triglycerides \>150mg/dl reduced hdl \ 130mmhg systolic, or \>85mmhg diastolic elevated fasting glucose \>100mg/dl

Eligibility criteria:
inclusion criteria: * 21-75 years * metabolic syndrome (3 of the 5 components) * elevated waist circumference \>40inches in men, \>35inches in women * elevated triglycerides \>150mg/dl * reduced hdl \<40mg/dl in men, \<50mg/dl in women * elevated blood pressure \>130mmhg systolic, \>85mmhg diastolic * elevated fasting glucose \>100mg/dl exclusion criteria: * diabetes mellitus * stage 3 hypertension \>180mmhg systolic, \>110mmhg diastolic office blood pressure * history of non-diabetic kidney disease * myocardial infarction of unstable angina within the past 6 months * history of liver disease * history of malignancy * history of drug or alcohol abuse * treatment with corticosteroids * pregnancy or lactating women of women of child bearing potential who are not willing to use reliable contraception method during the study
an mhealth strategy to reduce pre-eclampsia and infant death in tanzania

Conditions: Pre-Eclampsia; Eclampsia; Hypertension, Pregnancy-Induced

Summary: the core of this study is a cluster randomized controlled trial (rct) of antenatal clinics which are located in four districts in tanzania. we are conducting an effectiveness (pragmatic) rather than an efficacy (explanatory) trial because we are looking to measure the degree of benefit under 'real world' conditions. although pragmatic and carried out in real world conditions, the proposed size and scope of the trial will allow us to achieve a robust evaluation of outcomes and determine the effectiveness of our intervention. a cluster design is the most appropriate type of methodology (rather than individual randomization by pregnant woman) as the intervention can be delivered to the entire health facility (of those facilities in the intervention group). the intervention is to implement an mhealth strategy to improve detection and management of pe (pre-eclampsia). this study is a multi-level, mixed-methods design that includes a cluster-randomized controlled trial (rct) of antenatal clinics in rural tanzania. thirty health facilities have been randomized to control facilities and thirty facilities have been randomized to intervention clinics. all randomized clinics have upgraded antenatal care (anc) and skilled birth attendants present. nurses in the intervention clinics in this cluster arm will receive mhealth-based education in detection and management of pe and will be instructed and encouraged to follow a guideline-driven approach supported by mhealth (educational modules that provide decision support and reminders through the facility smartphone/tablet). at all antenatal visits, pregnant women will have their blood pressures measured and urine assessed for proteinuria, and, the result will be automatically sent by sms (short message service) with a unique patient identifier to a central site for monitoring and tracking. community health workers (chws) linked to the facility site and local communities will be instructed on which women to have follow-up visits within their communities. for all those women found to be at risk for pe (as well as other high risk maternal conditions), an sms will be sent to the chw, and, the nurses at the anc recommending timely follow-up and protocol steps for management at that facility or for transfer for further monitoring and management at a higher-level facility. the nurses participating in the study have been drawn from the health facilities themselves, in both control and intervention arms. quantitative data will be collected on an ongoing basis through the mobile platform. women are eligible for recruitment between 15 weeks and 36 weeks gestation.


Eligibility criteria:
inclusion criteria: * at least 5 months pregnant exclusion criteria: * unable to provide consent.

Keywords: pre-eclampsia eclampsia mhealth mobile health gestosis hypertension, pregnancy-induced
pharmaco-neuroimaging studies of approach/avoidance behaviors and post-mortem studies: study 1.2 (stress manipulation)

Conditions: Major Depression in Remission

Summary: this study investigates how remitted individuals with past major depressive disorder (mdd) make approach-avoidance decisions and which brain regions are implicated in such decisions. information collected through mri and behavioral tasks will be used to predict depressive symptoms in the future.

the overarching goals of this research are to investigate: (1) neural substrates of approach/avoidance behaviors in remitted mdds; (2) stress-induced signaling in remitted individuals with past mdd; (3) neural markers that prospectively predict disease course. this will be achieved through an innovative method of using functional magnetic resonance imaging (fmri) during an approach/avoidance decision-making task.

Eligibility criteria:
inclusion criteria for all participants: * all genders, races, and ethnic origins, aged between 18 and 45 * capable of providing written informed consent, and fluent in english * right-handed * absence of any psychotropic medications for at least 2 weeks * has a smartphone (iphone or android) (needed for ecological momentary assessment) inclusion criteria for "remitted mdd" group: * meets inclusion criteria for all subjects, plus: * history of mdd as defined by dsm-5 * absence of anxiety disorder for the past two months exclusion criteria for all participants: * subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. these patients will be immediately referred to appropriate clinical treatment * pregnant women or women of childbearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, iud, s/p tubal ligation, or partner with vasectomy) * serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease * history of seizure disorder * history of psychiatric illnesses, other than depression or anxiety disorders among the current mdd and remitted mdd groups * history of substance use disorder or alcohol use disorder (as these terms are defined by dsm-5); except depressed subjects may have a history of 'mild' substance/alcohol use disorder only if it ended as least 12 months ago * history of cocaine or stimulant use or dopaminergic drugs * history or current diagnosis of dementia, or a score of \< 26 on the mini mental state examination at the screening visit; * patients with mood congruent or mood incongruent psychotic features * current use of other psychotropic drugs * clinical or laboratory evidence of hypothyroidism * patients with a lifetime history of electroconvulsive therapy (ect) * failure to meet standard mri safety requirements * abnormal ecg and lab results * history of seizure disorder